XML 36 R21.htm IDEA: XBRL DOCUMENT
v3.20.1

Segment Information (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Segment Information [Abstract] |
Segment Information | The following tables show our segment revenue and income (loss) from operations for the three months ended March 31, 2020 and 2019 (in thousands), respectively.
Three Months Ended March 31, 2020 |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 66,008 |  |  | $ | — |  |  | $ | — |  |  | $ | 66,008 |
Product sales, net |  |  | — |  |  |  | 15,159 |  |  |  | — |  |  |  | 15,159 |
Licensing and other royalty revenue |  |  | 3,598 |  |  |  | — |  |  |  | (804 | ) |  |  | 2,794 |
Total commercial revenue |  | $ | 69,606 |  |  | $ | 15,159 |  |  | $ | (804 | ) |  | $ | 83,961 |
R&D revenue under collaborative agreements |  | $ | 48,491 |  |  | $ | 915 |  |  | $ | — |  |  | $ | 49,406 |
Total segment revenue |  | $ | 118,097 |  |  | $ | 16,074 |  |  | $ | (804 | ) |  | $ | 133,367 |
Total operating expenses |  | $ | 135,426 |  |  | $ | 61,334 |  |  | $ | (2,266 | ) |  | $ | 194,494 |
Loss from operations |  | $ | (17,329 | ) |  | $ | (45,260 | ) |  | $ | 1,462 |  |  | $ | (61,127 | )
Three Months Ended March 31, 2019 |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 59,711 |  |  | $ | — |  |  | $ | — |  |  | $ | 59,711 |
Product sales, net |  |  | — |  |  |  | 6,754 |  |  |  | — |  |  |  | 6,754 |
Licensing and other royalty revenue |  |  | 1,623 |  |  |  | — |  |  |  | — |  |  |  | 1,623 |
Total commercial revenue |  | $ | 61,334 |  |  | $ | 6,754 |  |  | $ | — |  |  | $ | 68,088 |
R&D revenue under collaborative agreements |  | $ | 160,556 |  |  | $ | 157,062 |  |  | $ | (88,492 | ) |  | $ | 229,126 |
Total segment revenue |  | $ | 221,890 |  |  | $ | 163,816 |  |  | $ | (88,492 | ) |  | $ | 297,214 |
Total operating expense |  | $ | 114,515 |  |  | $ | 137,610 |  |  | $ | (76,446 | ) |  | $ | 175,679 |
Income from operations |  | $ | 107,375 |  |  | $ | 26,206 |  |  | $ | (12,046 | ) |  | $ | 121,535 |
The following table shows our total assets by segment at March 31, 2020 and December 31, 2019 (in thousands), respectively.
Total Assets |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
March 31, 2020 |  | $ | 3,376,169 |  |  | $ | 559,921 |  |  | $ | (845,177 | ) |  | $ | 3,090,913 |
December 31, 2019 |  | $ | 3,478,081 |  |  | $ | 599,250 |  |  | $ | (844,219 | ) |  | $ | 3,233,112 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration